| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 7 Aug 2025 | 8 Jul 2025 |
| Quarterly Results Biocon Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2025 ,inter alia, to consider and approve Board Meeting Intimation to approve and take on record the un-audited standalone and consolidated financial results of the Company for the quarter ended June 30, 2025 (As Per BSE Announcement dated on 08.07.2025) Financial Results for the Quarter ended June 30, 2025 (As Per BSE Announcement Dated on: 07.08.2025) | ||
| Board Meeting | 9 Jul 2025 | 9 Jul 2025 |
| Outcome of Board Meeting - Appointment of Interim Company Secretary and Compliance Officer | ||
| Board Meeting | 26 Jun 2025 | 26 Jun 2025 |
| Outcome of Board Meeting | ||
| Board Meeting | 8 May 2025 | 2 Apr 2025 |
| Biocon Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/05/2025 inter alia to consider and approve Board Meeting Intimation Financial Results for the Quarter and Year ended March 31, 2025 Recommended a final dividend at the rate of 10% i.e. Re. 0.50/- per equity share of face value of Rs. 5/- each for the financial year ended March 31, 2025, subject to Shareholders approval at the ensuing Annual General Meeting (AGM). Pursuant to Regulation 42 of SEBI Listing Regulations, the Company has fixed Friday, July 04, 2025 as the record date for determining entitlement of Members to final dividend for the financial year ended March 31, 2025. The dividend will be paid on or before September 05, 2025. (As Per BSE Announcement Dated on :08.05.2025) Intimation of the approval of the audited consolidated financial statements for the financial year March 31, 2025 (As Per BSE Announcement Dated on 16.06.2025) | ||
| Board Meeting | 23 Apr 2025 | 20 Apr 2025 |
| Biocon Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/04/2025 inter alia to consider and approve To consider and approve the proposal for raising of funds by way of issue of equity shares or any other eligible securities through one or more of the permissible modes including but not limited to qualified institutions placement rights issue preferential issue further public offer etc. Outcome of Board Meeting (As Per Bse Announcement Dated on :23.04.2025) | ||
| Board Meeting | 4 Apr 2025 | 1 Apr 2025 |
| Biocon Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/04/2025 inter alia to consider and approve Intimation of Board meeting for raising funds through issuance of Commercial Papers or through any other mode Issuance of Commercial Papers up to an amount not exceeding Rs. 600 Crores in one or more tranches on private placement basis (As Per Bse Announcement Dated on 04.04.2025) | ||
| Board Meeting | 30 Jan 2025 | 3 Jan 2025 |
| BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2025 inter alia to consider and approve the un-audited standalone and consolidated financial results for the quarter and nine months ended December 31 2024 amongst other routine matters. Outcome of Board Meeting dated 30.01.2025 (As Per Bse Announcement Dated on 30.01.2025) | ||
| Board Meeting | 27 Jan 2025 | 22 Jan 2025 |
| BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2025 ,inter alia, to consider and approve Raising of Funds through issuance of Commercial Papers (CPs) or through any other mode on private placement basis. Outcome of Board Meeting held on 27.01.2025 (As Per BSE Announcement Dated on 27/01/2025) | ||
| Board Meeting | 30 Oct 2024 | 3 Oct 2024 |
| BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2024 inter alia to consider and approve Intimation for board meeting Unaudited Standalone and Consolidated Financial Results for quarter and half-year ended September 30, 2024 Outcome of Board Meeting dated October 30, 2024 (As Per BSE Announcement dated on 30.10.2024) | ||
The inspection, held between August 26 and September 3, covered drug substance manufacturing units, quality control labs, microbiology labs and warehouses.
The drug shall be used to treat diet and exercise for improvement of glycemic control in adults with type 2 diabetes.
Here are some of the stocks that may see significant price movement today: Interglobe Aviation, Tata Consultancy, Oil India, etc.
Biosimilars revenue grew 18% YoY to ₹2,458 crore in the quarter. This growth was driven by sustained global demand
As per the company’s regulatory filing, Kristy is currently available in the European Union and Canada markets from 2022.
Here are some of the stocks that may see significant price movement today: United Spirits, Biocon, NATCO Pharma, etc.
Here are some of the stocks that may see significant price movement today: Hyundai Motor, Biocon, Zee Entertainment, etc.
Biocon has appointed Kotak Mahindra Capital, Goldman Sachs (India), and BofA Securities India as lead advisors for the transaction
In its filing with the bourses, the company reported that the current contract period of 36 months has been extended for an additional six months.
As per the company’s filing with the bourses, Biocon Biologics has developed and manufactured this injection while Yoshindo Inc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
